$4.660
-0.010 (-0.21%)Zum Schluss
CVAC-News
CVAC-Events
Inventiva Appoints New Leadership Team Members
Inventiva (IVA) announced three new members of its leadership team: Axel-Sven Malkomes as CFO, Susan Coles as chief legal officer, and Pamela Herbster as chief people officer. Former CFO Jean Volatier will transition to the role of EVP finance and corporate social responsibility, where he will continue to support the company on strategic priorities. Malkomes was most recently CFO at publicly CureVac (CVAC). Coles comes to Inventiva from Vivet Therapeutics, where she was head of legal and finance. Herbster comes to Inventiva from Sage Therapeutics, where she led both human resources and business operations.
Evotec Appoints Ingrid Muller as COO
Evotec (EVO) announced the appointment of Ingrid Muller as COO. Muller will be joining Evotec's management board, effective May 1. In her role as COO, Muller will oversee Evotec's global operations and implementation of the Horizon initiative. Most recently, Muller served as VP portfolio strategy and execution at CureVac (CVAC).
BioNTech Completes CureVac Acquisition with 184,071,410 Shares Validly Tendered
BioNTech (BNTX) announced that 184,071,410 shares of CureVac (CVAC), representing approximately 81.74% of CureVac's issued and outstanding shares, were validly tendered and not properly withdrawn prior to the expiration of the initial offering period at 9:00 a.m. Eastern Time on December 3, 2025. As a result, the minimum condition for the exchange offer has been satisfied, and all validly tendered shares have been accepted. All closing conditions related to the completion of the post-offer reorganization have now been satisfied. BioNTech will now proceed to deliver BioNTech American Depositary Shares to the holders of CureVac shares who have tendered their shares, to close the transaction, as set out in more detail in the offer documents. BioNTech also announced that the subsequent offering period has commenced. CureVac shareholders who have not yet tendered their shares may still tender during the subsequent offering period, which will expire at 12:01 a.m. Eastern Time on Thursday, December 18, 2025. No guaranteed delivery procedures apply. The parties will initiate the post-offer reorganization as promptly as practicable following the expiration of the subsequent offering period. The post-offer reorganization will result in non-tendering holders of CureVac shares receiving BioNTech ADSs pursuant to the post-offer reorganization. Non-tendering holders of CureVac shares who receive BioNTech ADSs pursuant to the post-offer reorganization generally will be subject to a 15% Dutch dividend withholding tax.
BioNTech Provides Update on Its Exchange Offer for CureVac Shares
BioNTech (BNTX) announced the approval of matters relating to the exchange offer for all outstanding shares of CureVac (CVAC) at the extraordinary general meeting held by CureVac on November 25, 2025. At the EGM, over 99.16% of votes cast by CureVac shareholders were in favor of the proposals relating to the Offer. BioNTech expects to complete the pending Offer as soon as reasonably practicable. CureVac shareholders are advised to tender their shares by 6:00 p.m. Eastern Time on Tuesday, December 2, 2025, to ensure processing before the scheduled expiration time of 9:00 a.m. Eastern Time on Wednesday, December 3, 2025. Although the Offer technically expires at 9:00 a.m. Eastern Time on December 3, 2025, operational deadlines at the Depository Trust Company and the exchange agent require shares to be tendered by 6:00 p.m. Eastern Time on December 2, 2025. No guaranteed delivery procedures apply. Assuming that the Offer expires at 9:00 a.m. Eastern Time on December 3, 2025, the exchange ratio is 0.05363 of a BioNTech ADS per CureVac share. This calculation of the Exchange Ratio is based on the volume weighted average price of a BioNTech ADS as reported on Nasdaq for each of the 10 consecutive trading days ending on, and including, November 25, 2025, or $101.88. If the Offer is extended, BioNTech will recalculate the Exchange Ratio based on the later expected final expiration time and announce the new exchange ratio by issuing a press release.
CureVac anticipates funding will last until 2028
Cash and cash equivalents totaled EUR 416.1 million as of September 30, 2025, compared with EUR 481.7 million at year-end 2024. During the first nine months of 2025, cash was mainly used for operating activities, primarily to support ongoing research and development in oncology precision immunotherapies, prophylactic vaccines, and continued development of CureVac's mRNA technology. Cash outflow decreased significantly compared to the same period in 2024, mainly due to: Non recurrence of extraordinary payments in the prior year related to the termination of raw material commitments and contract manufacturing organization-related arbitration awards for the first-generation COVID-19 vaccine CVnCoV, and the strategic restructuring initiated in July 2024 reduced personnel expenses and introduced broader cost-saving measures across the organization. The company reaffirms its expected cash runway into 2028.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.